About Zilico
Zilico is developing the next generation of cancer diagnostics that will provide real-time diagnosis for cervical cancer and reduce the inherent subjectivity of current methods. Two applications are under development: the first for the referral market and the second for the screening market.
Since incorporation in 2006, Zilico has focused on developing a research-based instrument into a device (system) appropriate for commercial manufacture and routine use by medical practitioners. The Zilico system consists of a handheld device and a base unit together with a single-use disposable sleeve for each test. Clinical data on 500 women has demonstrated superior performance over existing diagnostic procedures and provided Zilico with the confidence to embark on a multi-centre clinical trial that started in April 2009. Pre-production devices are being used in these trials.
Following successful completion of the trial, Zilico plans to launch the first application in Europe and subsequently in the USA and the rest of the world. The clinical trials for the second application, scheduled for 2011, will necessarily be larger in scope. This will be launched in 2013.